Literature DB >> 19398965

Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study.

C Skert1, D Damiani, A Michelutti, F Patriarca, M Arpinati, C Filì, P Lucchi, M Malagola, C Bergonzi, A Roccaro, A Peli, D Ricotta, L Caimi, R Fanin, M Baccarani, D Russo.   

Abstract

The role of different cytokines and cells of immune system in the pathogenesis of chronic GVHD (cGVHD) is still controversial. Earlier studies, which were either retrospective or analysed one or a few factors, did not show unequivocal results. We prospectively evaluated cytokine levels and lymphocyte subsets in 30 patients who underwent Allo-SCT to investigate their possible correlation with cGVHD. Levels of IL-4, IL-6, IL-10, IFN-gamma, tumour necrosis factor-alpha (TNF-alpha) and its soluble receptors were assessed by ELISA in 30 patients at different times after SCT. Lymphocyte subsets were evaluated by flow cytometry in peripheral blood at the same times as cytokines. A multivariate analysis was performed using principal component analysis and multi-factor ANOVA (analysis of variance). Eighteen patients developed cGVHD at a median time of 6 months (range, 5-9) after SCT. In multivariate analysis, we observed a correlation between cGVHD and clusters of cytokines and lymphocyte subsets from the third to the sixth month after SCT. These clusters changed their composition over time, but they constantly included natural killer (NK) and CD152+ T cells as negative predictors of cGVHD. TNF-alpha prevailed among other cytokines before the onset of cGVHD. This prevalence could be related partly to the defect of immunoregulatory cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398965     DOI: 10.1038/bmt.2009.80

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  16 in total

Review 1.  The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease.

Authors:  Hong-Gang Ren; Djamilatou Adom; Sophie Paczesny
Journal:  Expert Rev Clin Immunol       Date:  2018-04-19       Impact factor: 4.473

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

Authors:  Sophie Paczesny; Frances T Hakim; Joseph Pidala; Kenneth R Cooke; Julia Lathrop; Linda M Griffith; John Hansen; Madan Jagasia; David Miklos; Steven Pavletic; Robertson Parkman; Estelle Russek-Cohen; Mary E D Flowers; Stephanie Lee; Paul Martin; Georgia Vogelsang; Marc Walton; Kirk R Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-30       Impact factor: 5.742

Review 3.  Biomarkers in chronic graft-versus-host disease.

Authors:  Jacob Rozmus; Kirk R Schultz
Journal:  Expert Rev Hematol       Date:  2011-06       Impact factor: 2.929

4.  Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation.

Authors:  Gregory A Yanik; Shin Mineishi; John E Levine; Carrie L Kitko; Eric S White; Mark T Vander Lugt; Andrew C Harris; Thomas Braun; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2011-12-10       Impact factor: 5.742

5.  Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.

Authors:  Enkhtsetseg Purev; Xin Tian; Georg Aue; Jeremy Pantin; Phuong Vo; Reem Shalabi; Robert N Reger; Lisa Cook; Catalina Ramos; Elena Cho; Tat'yana Worthy; Hanh Khuu; David Stroncek; Neal S Young; Richard W Childs
Journal:  Br J Haematol       Date:  2017-02-07       Impact factor: 6.998

6.  Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease.

Authors:  Yoshihiro Inamoto; Paul J Martin; Sophie Paczesny; Laura Tabellini; Amin A Momin; Christen L Mumaw; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Barry E Storer; Samir Hanash; John A Hansen
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-25       Impact factor: 5.742

Review 7.  Biologic markers of chronic GVHD.

Authors:  J Pidala; M Sarwal; S Roedder; S J Lee
Journal:  Bone Marrow Transplant       Date:  2013-07-22       Impact factor: 5.483

8.  Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.

Authors:  Jeremy Pantin; Xin Tian; Avni A Shah; Roger Kurlander; Catalina Ramos; Lisa Cook; Hahn Khuu; David Stroncek; Susan Leitman; John Barrett; Theresa Donohue; Neal S Young; Nancy Geller; Richard W Childs
Journal:  Am J Hematol       Date:  2013-09-03       Impact factor: 10.047

9.  Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.

Authors:  L Grkovic; K Baird; S M Steinberg; K M Williams; D Pulanic; E W Cowen; S A Mitchell; F T Hakim; K J Martires; D N Avila; T N Taylor; R B Salit; S D Rowley; D Zhang; D H Fowler; M R Bishop; R E Gress; S Z Pavletic
Journal:  Leukemia       Date:  2011-10-18       Impact factor: 11.528

Review 10.  Methods to Assess Disease Activity and Severity in Cutaneous Chronic Graft-versus-Host Disease: A Critical Literature Review.

Authors:  Hadir Shakshouk; Eric R Tkaczyk; Edward W Cowen; Rokea A El-Azhary; Shahrukh K Hashmi; Saad J Kenderian; Julia S Lehman
Journal:  Transplant Cell Ther       Date:  2021-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.